Italy gives the green light to the first pneumococcal vaccine specifically designed for adults: broader protection, single dose, and 8 unique serotypes included
A breakthrough in adult and senior prevention
With official approval from AIFA, Italy welcomes CAPVAXIVE®, the first 21-valent pneumococcal conjugate vaccine (V116) tailored specifically for the adult population. Developed by MSD, it provides unprecedented protection against Streptococcus pneumoniae, including 8 unique serotypes not covered by any other existing vaccine.
Why it’s revolutionary
V116 responds to real-world epidemiology, targeting the most dangerous serotypes for adults, especially those over 64 and people with comorbidities. Its estimated efficacy? Up to 76.4% prevention of IPD (invasive pneumococcal diseases) in over-64s, with an additional 12.4% coverage compared to the 20-valent vaccine (PCV20).
Moreover, it’s the only single-dose vaccine with such broad coverage — a key factor in increasing compliance and providing long-lasting protection.
Public health impact
According to Professor Caterina Rizzo, V116 could prevent over 11,000 cases of pneumococcal disease, both invasive and non-invasive, with potential savings of 56 million euros in direct and indirect healthcare costs.
This vaccine fits perfectly into the PNPV 2023-2025, which provides free access for 65-year-olds and adults over 18 with comorbidities.
The voice of physicians
General practitioners are ready to support the vaccination campaign. “Finally, a vaccine made for adults, with a single dose and long-lasting protection,” noted Dr. Silvestro Scotti from FIMMG. Pulmonologists like Prof. Micheletto also see its value: “This vaccine allows us to change the protection paradigm, with targeted and broader coverage for fragile patients.”
Innovation by MSD
“Our mission is to innovate in prevention,” said Nicoletta Luppi, President and CEO of MSD Italy. “CAPVAXIVE® is our concrete response to protect adults and seniors from the most severe forms of pneumococcal disease.”
Frequently Asked Questions (FAQ)
1. What is CAPVAXIVE®?
It’s a 21-valent conjugate vaccine against pneumococcus, developed by MSD and approved by AIFA for adults aged 18 and older.
2. What makes it unique?
It contains 8 exclusive serotypes not covered by any other pneumococcal vaccine.
3. Who gets it for free?
65-year-olds and adults over 18 with comorbidities, according to the PNPV 2023-2025.
4. Is only one dose required?
Yes, a single dose provides long-lasting protection.
5. What diseases does it prevent?
Invasive pneumococcal disease (IPD) and pneumococcal pneumonia.
6. What is the estimated prevention rate in seniors?
Up to 76.4% of IPD, with 12.4% more coverage than PCV20.
7. When will it be available?
As soon as regional health services implement the approval.
8. Why is adult pneumococcal vaccination important?
Because it prevents severe pneumonia, sepsis, and meningitis, especially in vulnerable groups.
9. Does it replace older vaccines?
It provides broader protection, but your doctor will advise based on your health profile.
10. Where can I learn more?
From your GP or local vaccination centers.
Leave a Reply